"Botulinum Toxins, Type A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serotype of botulinum toxins that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25.
| Descriptor ID |
D019274
|
| MeSH Number(s) |
D08.811.277.656.300.480.153.100 D08.811.277.656.675.374.153.100 D12.776.097.156.100 D23.946.123.179.050
|
| Concept/Terms |
Botulinum Toxins, Type A- Botulinum Toxins, Type A
- Botulinum Neurotoxin A
- Neurotoxin A, Botulinum
- Clostridium botulinum A Toxin
- Clostridium Botulinum Toxin Type A
- Botulinum A Toxin
- Toxin, Botulinum A
- Botulinum Toxin Type A
|
Below are MeSH descriptors whose meaning is more general than "Botulinum Toxins, Type A".
Below are MeSH descriptors whose meaning is more specific than "Botulinum Toxins, Type A".
This graph shows the total number of publications written about "Botulinum Toxins, Type A" by people in this website by year, and whether "Botulinum Toxins, Type A" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 2 | 0 | 2 |
| 1999 | 2 | 0 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 1 | 1 | 2 |
| 2004 | 5 | 0 | 5 |
| 2005 | 5 | 1 | 6 |
| 2006 | 4 | 1 | 5 |
| 2007 | 3 | 0 | 3 |
| 2008 | 4 | 1 | 5 |
| 2009 | 3 | 1 | 4 |
| 2010 | 3 | 0 | 3 |
| 2011 | 7 | 1 | 8 |
| 2012 | 3 | 0 | 3 |
| 2013 | 3 | 1 | 4 |
| 2014 | 5 | 0 | 5 |
| 2015 | 3 | 0 | 3 |
| 2016 | 4 | 2 | 6 |
| 2017 | 4 | 0 | 4 |
| 2018 | 3 | 1 | 4 |
| 2019 | 3 | 0 | 3 |
| 2020 | 5 | 1 | 6 |
| 2021 | 5 | 0 | 5 |
| 2022 | 4 | 0 | 4 |
| 2023 | 7 | 0 | 7 |
| 2024 | 2 | 0 | 2 |
| 2025 | 1 | 0 | 1 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Botulinum Toxins, Type A" by people in Profiles.
-
Effects of membrane properties on the binding activities of the HN and HC heavy-chain domains of botulinum neurotoxin A. Biochim Biophys Acta. 2016 12; 1864(12):1678-1685.
-
Antigenic sites on the HN domain of botulinum neurotoxin A stimulate protective antibody responses against active toxin. Sci Rep. 2015 Oct 28; 5:15776.
-
The C-terminal heavy-chain domain of botulinum neurotoxin a is not the only site that binds neurons, as the N-terminal heavy-chain domain also plays a very active role in toxin-cell binding and interactions. Infect Immun. 2015 Apr; 83(4):1465-76.
-
Use of injectable spasticity management agents in a cancer center. Support Care Cancer. 2013 May; 21(5):1227-32.
-
Inhibition in?vivo of the activity of botulinum neurotoxin A by small molecules selected by virtual screening. Toxicon. 2012 Nov; 60(6):1180-90.
-
Location of the synaptosome-binding regions on botulinum neurotoxin B. Biochemistry. 2012 Jan 10; 51(1):316-28.
-
Antibodies against a synthetic peptide designed to mimic a surface area of the H chain of botulinum neurotoxin A. Immunol Lett. 2012 Feb 29; 142(1-2):20-7.
-
Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B. J Neuroimmunol. 2011 Dec 15; 240-241:121-8.
-
Antibody and T cell recognition of the light chain of botulinum neurotoxin A in two high-responder mouse strains. Immunobiology. 2012 Jan; 217(1):1-7.
-
Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule. Immunobiology. 2012 Jan; 217(1):17-27.